201 E. FIFTH STREET, CINCINNATI, OH
Provides Strategic Bridge Financing to Realbotix LLC in Support of Pending Acquisition
News, Articles of Incorporation, Material Contracts
Announces 1-for-10 Reverse Stock Split
Reports Q1 2026 Progress at Proteomedix, Including Two New Peer-Reviewed Publications and Initiation of U.S. Validation Study
Onconetix, Inc. Holds Special Meeting; Approves Reverse Stock Split Proposal
Director Resignations - Andrew Oakley and Thomas Meier Step Down
Amended material disclosure
David White Appointed Chief Executive Officer of Onconetix, Inc.
Q2
Q1
FY 2025
Q3
FY 2024
Notice of Late Filing for Annual Report
Prospectus Filed Pursuant to Rule 425
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Amended Registration Statement for Securities
S-1
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Post-Effective Amendment to Registration Statement
Submission Upload
Correspondence